Skip to main content

CRUK Therapeutic Discovery Laboratories

Menu
  • Home
  • About us
  • Our approach
  • Our science
  • News
  • Careers
  • Contact Us

You are here

HomePublications
  • News

  • Events

  • Publications

  • Cell-based screening to identify repressors of wild type and mutated telomerase reverse transcriptase gene promoter activity

    20/04/2016

    Cellular immortality is a near-universal phenotype of cancer cells with the central role played by the multicomponent telomerase complex firmly...

    Read more
  • Lead generation and optimisation of a series of novel glutaminase (GLS) inhibitors

    07/11/2015

    Glutamine is an essential nutrient for cancer cells and is used to support cancer cell growth. Glutamine is converted to glutamate by the enzyme...

    Read more
  • Identification of potent, cell active MTH1 inhibitors and their use in target validation studies

    07/11/2015

    MTH1 is a protein that sanitizes oxidized dNTPs in the cell. It preferentially hydrolyzes 8-oxo-dGTP and 2-OH-dATP to their corresponding...

    Read more
  • Development of selective probe compounds to help unlock cancer's secrets

    03/11/2015

    The development of targeted therapies is a critical cornerstone in the fight against Cancer. A key part of this process is the development of...

    Read more
  • Identification of appropriate in vivo models to demonstrate the phenotypic consequence of modulating the autotaxin/lysophosphatidic acid receptor (ATX/LPAR) pathway

    02/11/2015

    Autotaxin (ATX) is an extracellular lyso-phospholipase that cleaves choline from lysophosphatidylcholine to produce lysophosphatidic acid (LPA)....

    Read more
  • GLS1 (Glutaminase) inhibitor development

    21/09/2015

    The GLS1 (glutaminase) project is part of an alliance between AstraZeneca and Cancer Research Technology to develop drugs targeting cancer...

    Read more
  • Complementary approaches to study histone lysine demethylases (KDM) for drug discovery

    02/09/2015

    The interest in dissecting the relevance of different jumonji domain (JMJ)-containing KDMs as therapeutic targets in cancer and human disease is...

    Read more
  • Strategies for targets sensitive to Redox Cycling Compounds

    02/09/2015

    Pan-assay Interference Compounds (PAINS) are often, if not always, present in screening libraries. The activity of these compounds is not...

    Read more
  • Biophysical Techniques For Hit Validation During Small Molecule Drug Discovery

    02/09/2015

    The validation of hits resulting from a high throughput screening campaign is a critical part of the development of small molecule drugs. After...

    Read more
  • Screening for small molecule inhibitors of a transcription factor target implicated in cancer

    02/09/2015

    The Northern Institute for Cancer Research (NICR) and CRT have recently collaborated on a screening campaign in order to initiate a drug discovery...

    Read more
  •  
  • 1 of 2
  • › Next

Our History

The Discovery Laboratories were established in 2003 with a focus to grow a small molecule and biological therapeutics discovery function that would be available to all CRUK- funded scientists and those working more broadly in cancer research. Launched as the in-house drug discovery unit of Cancer Research Technology, we were known as the CRT Discovery Laboratories (CRT-DL) until we rebranded to become the CRUK Therapeutic Discovery laboratories in July 2017.

MEDIA ENQUIRIES

For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.

Top

Quick links

  • News
  • Careers
  • Contact Us
  • About Us
    • Senior Management
    • Cancer Biology Advisory Board
  • Our Approach
    • Alliance Model
    • Track Record
  • Our Science
    • Target Validation and Disease Positioning
    • Lead Identification
    • Lead Optimisation
  • © CRUK Therapeutic Discovery Laboratories 2021
  • Terms & Conditions
  • Privacy Statement
  • How We Use Cookies
  • Legal Status
  • Modern Slavery Statement

This site uses cookies. Click here to find out more and how to refuse cookies.

Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place London E20 1JQ UK.

  • Discovery Laboratories

  • commercial.cruk.org